Two schools added to biodefense research network

Bioterrorism

Jun 1, 2005 (CIDRAP News) – A federally funded network of academic centers that do research on bioterrorism and emerging infectious diseases has been rounded out with the addition of the University of California, Irvine, and Colorado State University in Fort Collins.

The National Institute of Allergy and Infectious Diseases (NIAID) said today that the two schools have been named "Regional Centers of Excellence for Biodefense and Emerging Infectious Disease Research (RCE)." Each school will receive about $10 million a year over the next 4 years to lead a regional research consortium.

At the University of California, Irvine, Alan G. Barbour, MD, will head a consortium that includes four other University of California campuses and 11 other regional universities and research institutions, the NIAID said.

Barry J. Beaty, PhD, of Colorado State will lead a consortium that includes five other universities along with small-business partners. The consortium will also collaborate with the US Centers for Disease Control and Prevention, whose Division of Vector-Borne Infectious Diseases operates in Fort Collins.

"The addition of these two new RCEs expands the network’s scientific reach to cover some poorly understood diseases and new research needs," the NIAID said. "For example, researchers in the new centers have expertise in equine encephalitis and other viral diseases that can be transmitted to people by mosquitoes. The centers also add expertise in hantaviruses, as well as in the development of diagnostics and animal models of disease."

The NIAID set up the biodefense research network in 2003 with grants to eight institutions: Duke University, Harvard Medical School, the New York State Department of Health, University of Chicago, University of Maryland, University of Texas Medical Branch (Galveston), University of Washington, and Washington University in St. Louis.

The network's mission includes developing and testing vaccines and "therapeutic and diagnostic concepts" and providing facilities and scientific support to first responders in case of a national biodefense emergency, the NIAID said.

See also:

Jun 1 NIAID news release

This week's top reads

  1. FDA significantly limits COVID-19 vaccine recommendations

    Critics said today’s announcement is more evidence of the current administration’s willingness to undermine public trust in vaccines.

    Stephanie Soucheray
    FDA building

  2. Woman dies of Creutzfeldt-Jakob almost 50 years after taking prion-contaminated growth hormone

    The patient, who presented with gait imbalance and tremors, wasn't diagnosed until she was in a coma, shortly before she died.

    Mary Van Beusekom
    Woman in hospital bed

  3. Meta-analysis: Zika-infected pregnant moms 4 times more likely to have babies with microcephaly

    Five of 22 studies noted that over 50% of newborns had microcephaly, and the same number of studies observed that over 5% had congenital Zika syndrome. 

    Mary Van Beusekom

  4. HHS expected to discontinue COVID vaccine recommendations for some groups

    When CDC advisers widened their recommendation in 2023, most members were swayed by data, including those for long COVID, showing that no group is at low risk for the virus.

    Lisa Schnirring

  5. WHO advisers say current strains OK for COVID vaccine production

    Current vaccine strains show high neutralization against the latest variants, but the LP.8.1 antigen may provide similar or moderately higher cross-reactive antibody response.

    Lisa Schnirring
    senior vaccination

  6. US measles outbreak grows to 1,024 cases

    Texas remains the country's hot spot, with 718 cases. 

    Chris Dall
    Doctor treating child with measles

  7. Texas announces more measles cases, including first in Dallas area

    Two cases near the Dallas area are now included in the large outbreak, which now totals 717 cases.

    Lisa Schnirring

  8. Moderna pulls licensing submission for combo flu-COVID vaccine

    Moderna's combination vaccine was intended for adults 50 and older. 

    Stephanie Soucheray

  9. Saudi Arabia confirms 9 MERS cases, including hospital cluster

    Since 2023, the country has ramped up MERS-CoV testing as part of sentinel surveillance.

    Lisa Schnirring
    hospital isolation

  10. Mpox activity escalates in Sierra Leone

    Responding to the surge is a major focus, partly to prevent the spread to other West African countries. 

    Lisa Schnirring
    mpox virus

Our underwriters